[go: up one dir, main page]

MX2011009669A - Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. - Google Patents

Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.

Info

Publication number
MX2011009669A
MX2011009669A MX2011009669A MX2011009669A MX2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A
Authority
MX
Mexico
Prior art keywords
influence
excipients
pharmaceutical composition
controlled release
coating
Prior art date
Application number
MX2011009669A
Other languages
English (en)
Inventor
Michael Gottschalk
Hans Baer
Thomas Fuerst
Gerhard Renner
Thomas Rupp
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2011009669A publication Critical patent/MX2011009669A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención trata sobre una composición farmacéutica de liberación controlada, que consta de un núcleo, que consta de un ingrediente farmacéutico activo, donde el núcleo está revestido por una capa de revestimiento que proporciona resistencia y que tiene el efecto de proporcionar el perfil de liberación del ingrediente farmacéutico activo para que sea resistente a la influencia del etanol, en donde la capa de revestimiento que proporciona resistencia al etanol consta de al menos 70% por peso de una mezcla de una porción polimérica a) y una porción de excipientes b), donde la porción polimérica a) está presente en una cantidad de al menos 3.0% por peso calculada en el peso del núcleo y donde la porción polimérica a) consta de una mezcla de polímeros a1) y a2) con a1) 60 a 99% por peso, con base en el peso en seco de la mezcla polimérica, de un polímero de vinilo o un copolímero de vinilo esencialmente neutral insoluble en agua, y a2) 1 a 40% por peso, con base en el peso seco de la mezcla polimérica, de un copolímero amino (met) acrilato, que es soluble en un medio acuoso amortiguado hasta de ph 4.0 e insoluble al menos por encima de ph 5.0 y la porción de excipientes b) que consta de los excipientes b1) 60 a 250% por peso de un lubricante inerte no poroso b2) 0.1 a 25% por peso de un emulsionante y además o de manera alternativa a b2) b3) 0.1 a 30% por peso de un plastificante y de forma opcional b4) 1 - 35% por peso de un compuesto celulósico. donde los excipientes de la porción de excipientes b) se calculan en peso en seco de la porción polimérica a).
MX2011009669A 2009-03-18 2009-03-18 Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. MX2011009669A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/053177 WO2010105673A1 (en) 2009-03-18 2009-03-18 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients

Publications (1)

Publication Number Publication Date
MX2011009669A true MX2011009669A (es) 2011-12-14

Family

ID=40752823

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009669A MX2011009669A (es) 2009-03-18 2009-03-18 Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.

Country Status (10)

Country Link
US (1) US20110311631A1 (es)
EP (1) EP2408437A1 (es)
JP (1) JP5619131B2 (es)
KR (1) KR20120003436A (es)
CN (1) CN102365083A (es)
BR (1) BRPI0924427A2 (es)
CA (1) CA2755814A1 (es)
IL (1) IL214612A0 (es)
MX (1) MX2011009669A (es)
WO (1) WO2010105673A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339408B (es) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
ES2408343B2 (es) 2010-05-10 2014-07-17 Euro-Celtique, Sa Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
BR112013027484A8 (pt) 2011-06-17 2022-07-05 Evonik Roehm Gmbh Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato
US9844511B2 (en) * 2011-06-17 2017-12-19 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
US9668977B2 (en) 2011-06-17 2017-06-06 Evonik Röhm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンW R Grace & Co−Conn 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
EP2945994B1 (en) 2013-01-18 2018-07-11 Basf Se Acrylic dispersion-based coating compositions
JP6150564B2 (ja) * 2013-03-08 2017-06-21 杏林製薬株式会社 口腔内速崩壊性錠剤
US10064826B2 (en) * 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド 徐放性乱用抑止性液体充填剤形
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
HK1256865A1 (zh) * 2016-02-03 2019-10-04 Novartis Ag 有机化合物的盖伦制剂
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106727435B (zh) * 2016-12-26 2020-06-02 浙江工业大学 一种美托洛尔缓释胶囊及其制备方法
WO2018183881A1 (en) * 2017-03-31 2018-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceuticals ingredients
MX2020002790A (es) 2017-09-14 2020-08-20 Evonik Operations Gmbh Polimero y forma de dosis con propiedades de liberacion sostenida y resistencia contra la influencia de etanol.
MX2020005438A (es) 2017-12-20 2020-12-03 Purdue Pharma Lp Formas de dosificacion de sulfato de morfina disuasivas del abuso.
WO2019170485A1 (en) 2018-03-09 2019-09-12 Evonik Röhm Gmbh Polymer mixture with resistance against the influence of ethanol
KR102138253B1 (ko) * 2018-08-17 2020-07-29 한국유나이티드제약 주식회사 실로스타졸 서방성 제제
EP3883549A1 (en) * 2018-11-19 2021-09-29 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN112294777B (zh) * 2020-11-04 2022-07-05 南京康川济医药科技有限公司 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用
EP4366710A1 (en) * 2021-07-09 2024-05-15 Evonik Operations GmbH Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法
EP4527411A1 (en) * 2022-05-18 2025-03-26 Towa Pharmaceutical Co., Ltd. Membrane-forming composition, membrane-like composition, and use of same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU5775398A (en) * 1996-12-17 1998-07-15 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
DE19918435A1 (de) * 1998-07-23 2000-01-27 Roehm Gmbh Überzugs- und Bindemittel für orale oder dermale Arzneiformen
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AU2003270349A1 (en) * 2002-09-09 2004-03-29 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004285284B2 (en) * 2003-10-31 2010-03-25 Hexal Ag A process for the preparation of an active-ingredient-containing formulation with a coating
BRPI0606339A2 (pt) * 2005-01-28 2009-06-16 Euro Celtique Sa formas farmacêuticas resistentes a álcool
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
DE102006051020A1 (de) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
JP5965583B2 (ja) * 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
US9700520B2 (en) * 2007-09-21 2017-07-11 Evonik Roehm Gmbh PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol

Also Published As

Publication number Publication date
JP5619131B2 (ja) 2014-11-05
EP2408437A1 (en) 2012-01-25
BRPI0924427A2 (pt) 2016-01-26
CN102365083A (zh) 2012-02-29
WO2010105673A1 (en) 2010-09-23
CA2755814A1 (en) 2010-09-23
US20110311631A1 (en) 2011-12-22
JP2012520832A (ja) 2012-09-10
KR20120003436A (ko) 2012-01-10
IL214612A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
MX2011009669A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.
MX2011009667A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante el uso de un revestimiento compuesto de polímeros de vinilo neutrales y excipientes.
MX347227B (es) Composicion farmaceutica o nutraceutica con liberacion sostenida caracteristica y con resistencia contra la influencia del etanol.
WO2010064126A3 (en) Controlled release dosage forms
MX355662B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influencia de etanol.
WO2012085043A3 (en) Rapidly disintegrating, solid coated dosage form
BRPI0720626A2 (pt) Composição formadora de película, nanopartículas modificadas, revestimento resistente a risco, usos de um copolímero segmentado, e de nanopartículas modificadas
MX358196B (es) Composicion farmaceutica o nutraceutica con caracteristica de liberacion sostenida y con resistencia contra la influencia del etanol.
MX2017006858A (es) Composición farmacéutica o nutracéutica con resistencia a la influencia del etanol.
WO2010005726A3 (en) Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
NZ600123A (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
MX376383B (es) Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol
BRPI0823128A2 (pt) Composição farmacêutica de liberação controlada dependente do ph para não opioides com resistência contra a influência de etanol.
WO2009123759A3 (en) Therapeutic uses of biocompatible biogel compositions
BR112014002837A2 (pt) dispersão aquosa com baixo teor de formaldeído de um copolímero de vinil éster/etileno preparado por meio de copolimerização de emulsão de uma mistura de monômero; composição de adesivo; produto de cigarro; e uso da composição de adesivo
WO2010106314A3 (en) Formulation comprising avermectin particles coated with a photo - protecting agent
WO2009121970A3 (de) Schichtmaterial
MX356579B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
WO2010005732A3 (en) Composition and method of preparation of release systems for constant (zero-order) release of active agents
WO2014106116A3 (en) Therapeutic compositions comprising antibodies
WO2013012666A3 (en) Compounds, methods of making, and methods of use
WO2014179615A3 (en) Biodegradable copolymers, forming and using same
BR112012022363A2 (pt) forma de dosagem com liberação modificada
BR112013020581A2 (pt) "composição agroquímica, método de preparação da composição, uso de um copolímero e método de controle de fungos fitopatogênicos"
WO2012092486A3 (en) Modified release benzimidazole formulations

Legal Events

Date Code Title Description
FG Grant or registration